Close

BMO Capital Positive on VBI Vaccines (VBIV) Amid NRC COVID-19 Collaboration

March 31, 2020 10:11 AM EDT Send to a Friend
BMO Capital analyst Do Kim reiterated an Outperform rating and $5.00 price target on VBI Vaccines (NASDAQ: VBIV) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login